PharmaVOICE

4 days ago | pharmavoice.com | Alexandra Wilson Pecci

This audio is auto-generated. Please let us know if you have feedback. Nikolaus Friedreich is “definitely dead.” And he has been since 1882. At least, that’s what his gravestone says at the beginning of “Friedreich’s Back,” a marketing campaign for the drug Skyclarys, Biogen’s treatment for the ultra-rare genetic condition, Friedreich ataxia. But when Friedreich’s corpse reaches a hand up out of the ground, zombie-movie style, the ad takes a turn.

1 week ago | pharmavoice.com | Jonathan Gardner

This audio is auto-generated. Please let us know if you have feedback. Food and Drug Administration Commissioner Martin Makary has proposed a dramatic expansion of the agency’s powers to speed up drug reviews, announcing on Tuesday a plan to evaluate new medicines that address U.S. “national interests,” like a health crisis, in just one to two months.

1 week ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. A ban on pharma’s TV ads may finally be on the way. Sens. Bernie Sanders, I-Vt., and Angus King, I-Maine, introduced the End Prescription Drug Ads Now Act last week that would end pharma’s ability to advertise directly to consumers. If enacted, the bill would fulfill a goal of HHS Secretary Robert F.

1 week ago | pharmavoice.com | Kelly Bilodeau

This audio is auto-generated. Please let us know if you have feedback. The 340B Drug Pricing Program has long been a contentious issue for pharma. Aimed at providing discounted drugs to hospitals in lower income areas, pharma leaders argue the program is vulnerable to abuse and sometimes boosts hospital profits without helping patients. Now, the tide is turning towards possible changes to the policy.

1 week ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. Pharma’s middlemen are under fire. Known as the negotiators between health plans, pharmacies and drug companies, pharmacy benefit managers are currently entangled in a national conversation about reform. The pharma industry has long blamed PBMs for rising drug prices, pointing to opaque rebate and profit structures, and proposed policy shifts could take them to task.